RevMed's pancreatic cancer drug nears European approval

Following a green light from the FDA, European regulators have now recommended the approval of Revolution Medicines' Rasonque for pancreatic cancer. research legal Cancer Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Saved Stories Billing Log Out Reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Summit Search Log In Try STAT+ My Account My Account Settings Saved Stories Billing History Home Newsletter The Readout RevMed’s pancreatic cancer drug nears European…

Meghana Keshavan and Andrew Joseph · 2026-10-16

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

We’re leaving room for popcorn and intrigue tonight: The new A24 documentary, “You Can See Everything,” hits theaters today.

I remember back at the American Association for Clinical Chemistry meeting in 2016, a skeptical pathologist told me in advance of a purported Theranos data unveil:

Continue to STAT+ to read the full story…

Source: STAT News Pharma